Positron Emission Tomography–Derived Metrics Predict the Probability of Local Relapse After Oligometastasis-Directed Ablative Radiation Therapy-Reference-Cited by-同舟云学术

Positron Emission Tomography–Derived Metrics Predict the Probability of Local Relapse After Oligometastasis-Directed Ablative Radiation Therapy

Published:2022-03 Issue:2 Volume:7 Page:100864
ISSN:2452-1094
Container-title:Advances in Radiation Oncology
language:en
Short-container-title:Advances in Radiation Oncology

Author:

Greco Carlo^ORCID,Pares Oriol,Pimentel Nuno,Louro Vasco,Morales Javier,Nunes Beatriz,Antunes Inês,Vasconcelos Ana Luisa,Kociolek Justyna,Castanheira Joana,Oliveira Carla,Silva Angelo,Vaz Sofia,Oliveira Francisco,Carrasquinha Eunice,Costa Durval,Fuks Zvi

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference34 articles.

1. Oligometastases.

2. Consolidative radiotherapy for limited metastatic non–small-cell lung cancer;Iyengar;JAMA Oncol,2018

3. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial;Palma;Lancet,2019

4. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study;Gomez;J Clin Oncol,2019

5. Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 Gy radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer;Zelefsky;Int J Radiat Oncol Biol Phys,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer;Advances in Radiation Oncology;2024-07

2. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-05-14

3. Lesion Dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer;Journal of Nuclear Medicine;2023-08-31